September 2024 in “Journal of the American Academy of Dermatology” In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.
March 2016 in “West Indian medical journal” This study found no statistically significant relationship between androgenic alopecia and the PON1 ML55 and QR192 genetic polymorphisms, despite a higher frequency of the PON 55 L allele in patients.
24 citations
,
February 2011 in “The American journal of pathology” This study found that AIRE, a usually nuclear protein, is expressed in the cytoplasm of human epidermal and follicular keratinocytes and associates with the intermediate filament protein cytokeratin 17, potentially impacting ectodermal abnormalities in APECED syndrome.
April 2019 in “Journal of Investigative Dermatology” This study found that blocking LFA-1 signaling completely prevented the development of alopecia areata in C3H/HeJ mice, suggesting that LFA-1 plays a crucial role in the disease's pathogenesis and could be a target for new therapies.
2 citations
,
October 2000 in “Journal of Investigative Dermatology” AUC and APL are distinct conditions needing careful clinical assessment.
1 citations
,
October 2025 in “Journal of Allergy and Clinical Immunology” A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.
56 citations
,
December 2011 in “The Plant Journal” AGD1 is important for root hair development in Arabidopsis, working with phosphoinositide signaling and the actin cytoskeleton.
September 2024 in “Pigment Cell & Melanoma Research” This study found that mitochondrial fusion regulator Opa1 is crucial for maintaining melanocyte stem cells during the hair follicle cycle in mice, with Opa1 deficiency leading to impaired SCF-KIT signaling, reduced melanocyte populations, and early hair graying.
11 citations
,
March 2021 in “Dermatology and therapy” This study developed the Alopecia Areata Patient Priority Outcome (AAPPO), a new tool designed to measure and capture the symptoms and impacts of alopecia areata that matter most to patients.
July 2022 in “Journal of Investigative Dermatology” Arg1+ macrophages may play a role in Alopecia Areata, offering new treatment targets.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.
March 2026 in “JID Innovations” In a mouse model study, researchers found that mutations in Aire reduced alopecia areata frequency, while Notch4 mutations did not lead to the disease, likely due to proximity with a resistance gene.
August 2017 in “Seoul National University Open Repository (Seoul National University)” The study investigated the role of Aminoacyl-tRNA synthetase interacting multifunctional protein 1 (AIMP1) in hair follicle stem cell proliferation and its potential as a treatment for alopecia. AIMP1, when dissociated from the multi-tRNA synthetase complex, was found to be secreted by dermal papilla cells in a sonic hedgehog (Shh) signal-dependent manner. This secretion increased the proliferation of CD34+ hair follicle stem cells by promoting the wnt signaling pathway through inhibition of sFRP1, a known wnt antagonist. The research demonstrated that the N-terminal fragment of AIMP1 could be developed into a therapeutic peptide for hair loss. When applied topically to depilated mice, this peptide significantly accelerated hair growth, especially when formulated with carbomer. The findings highlighted a novel mechanism of AIMP1 action and its potential application in alopecia treatment.
September 2025 in “Journal of the American Academy of Dermatology” 5 citations
,
May 2022 in “Lara D. Veeken” This study reports the first case of diverse medium-sized visceral arterial aneurysms in a patient with functionally impaired A20, potentially linked to HA20, and its atypical presentation in East Asia.
2 citations
,
October 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” This study found that Aire‒/‒ mice spontaneously developed persistent AA-like lesions, highlighting a potential role for AIRE in hair follicle biology and pathogenesis of alopecia areata.
November 2021 in “International Journal of Trichology” This study found that androgenetic alopecia patients had significantly lower serum levels of paraoxonase 1, which correlated with disease severity and suggests a role of oxidative stress in its pathogenesis.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” This study shows that IKZF1 and the protein IKAROS may play a role in the development of alopecia areata, based on findings from both mouse models and human scalp tissues.
This study identified distinct immune differences in patients with alopecia areata, particularly those with atopic backgrounds, and highlighted the OX40 axis as a potential therapeutic target for the condition.
September 2017 in “Journal of Investigative Dermatology” This study found that in AGA, the risk allele at locus 2q35 alters WNT10A expression through EBF1, suggesting a potential androgen-dependent regulatory mechanism.
October 2023 in “Benha Journal of Applied Sciences” This study found that male patients with androgenetic alopecia had lower serum levels of the antioxidant enzyme paraoxonase 1 compared to healthy controls.
May 2018 in “The Journal of Immunology” In this study, daily treatment with angiotensin (1-7) significantly reduced disease severity in a mouse model of Systemic Lupus Erythematosus, suggesting potential for Mas agonists in future therapies.
1 citations
,
September 2024 in “Frontiers in Pharmacology” In this real-world study, aumolertinib was found to improve patient-reported outcomes and maintain high disease control and objective response rates similar to those reported in the AENEAS trial for advanced NSCLC patients, supporting its use in first-line treatment.
62 citations
,
January 2010 in “Hormone research in paediatrics” This study found that the R257X mutation in the AIRE gene is prevalent among Russian patients with autoimmune polyglandular syndrome type 1, particularly in those with hypoparathyroidism and chronic mucocutaneous candidiasis.
June 2026 in “Archives of Dermatological Research” In this study, the rs4541843 G > A variant was found to be significantly associated with increased risk and severity of alopecia areata, as well as elevated expression of hsa-miR-182-5p, suggesting their potential as molecular markers for diagnosis and severity assessment.
22 citations
,
November 2021 in “Dermatology and Therapy” This study found that the Alopecia Areata Patient Priority Outcomes questionnaire is a reliable and valid tool for measuring the severity and impact of hair loss in individuals with alopecia areata.
June 2026 in “bioRxiv (Cold Spring Harbor Laboratory)” This study found that inhibiting the interaction between HOTAIR and EZH2 can block pro-fibrotic gene expression in fibroblasts and interfere with tissue remodeling in systemic sclerosis patient skin.
15 citations
,
June 2019 in “Biochemical Journal” This study identified a heterozygous de novo mutation in the ODC1 gene causing a new disorder characterized by overgrowth and developmental delay, and suggests that DFMO treatment may help manage elevated ODC activity and putrescine levels.
7 citations
,
January 2018 in “Neurodegenerative Diseases” This study identified a new clinical variant of adult adrenomyeloneuropathy characterized by hypoplasia and agenesis of the corpus callosum, associated with a novel ABCD1 gene mutation.
2 citations
,
January 2021 in “The Scientific Journal of Al-Azhar Medical Faculty Girls” This study found that patients with alopecia areata had higher serum osteopontin levels and more eye abnormalities compared to healthy controls, although visual acuity was not affected.